Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,472 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of Renal Function on the Prognosis of Patients Receiving Atezolizumab/Bevacizumab Combination Therapy and Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma.
Takada H, Yamashita K, Osawa L, Komiyama Y, Nakakuki N, Muraoka M, Suzuki Y, Sato M, Takano S, Fukasawa M, Yamaguchi T, Maekawa S, Takahashi K, Uchimura K, Enomoto N. Takada H, et al. Among authors: yamashita k. Oncology. 2023;101(10):609-623. doi: 10.1159/000531111. Epub 2023 Jun 6. Oncology. 2023. PMID: 37279708
Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib.
Kaneko S, Tsuchiya K, Kurosaki M, Kirino S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Takeguchi T, Takeguchi Y, Nakanishi H, Itakura J, Takahashi Y, Himeno Y, Izumi N. Kaneko S, et al. Among authors: yamashita k. Hepatol Res. 2020 Jan;50(1):137-143. doi: 10.1111/hepr.13416. Epub 2019 Sep 6. Hepatol Res. 2020. PMID: 31349377
Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma.
Takada H, Kurosaki M, Tsuchiya K, Komiyama Y, Itakura J, Takahashi Y, Nakanishi H, Yasui Y, Tamaki N, Maeyashiki C, Kaneko S, Takaura K, Higuchi M, Okada M, Wang W, Osawa L, Sekiguchi S, Hayakawa Y, Yamashita K, Enomoto N, Izumi N. Takada H, et al. Among authors: yamashita k. Cancers (Basel). 2019 Aug 27;11(9):1256. doi: 10.3390/cancers11091256. Cancers (Basel). 2019. PMID: 31461985 Free PMC article.
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice.
Wang W, Tsuchiya K, Kurosaki M, Yasui Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Wang W, et al. Among authors: yamashita k. Cancers (Basel). 2019 Oct 9;11(10):1517. doi: 10.3390/cancers11101517. Cancers (Basel). 2019. PMID: 31601010 Free PMC article.
Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Kirino S, Tsuchiya K, Kurosaki M, Kaneko S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Okada M, Wang W, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Izumi N. Kirino S, et al. Among authors: yamashita k. PLoS One. 2020 Apr 20;15(4):e0231828. doi: 10.1371/journal.pone.0231828. eCollection 2020. PLoS One. 2020. PMID: 32310967 Free PMC article.
Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib.
Kaneko S, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Takeguchi T, Takeguchi Y, Nakanishi H, Itakura J, Takahashi Y, Himeno Y, Kurosaki M, Izumi N. Kaneko S, et al. Among authors: yamashita k. JGH Open. 2020 Oct 16;4(6):1183-1190. doi: 10.1002/jgh3.12420. eCollection 2020 Dec. JGH Open. 2020. PMID: 33319054 Free PMC article.
Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan.
Osawa L, Nakanishi H, Kurosaki M, Kirino S, Inada K, Yamashita K, Hayakawa Y, Sekiguchi S, Wang W, Okada M, Higuchi M, Komiyama Y, Takaura K, Takada H, Kaneko S, Maeyashiki C, Tamaki N, Yasui Y, Tsuchiya K, Itakura J, Takahashi Y, Enomoto N, Izumi N. Osawa L, et al. Among authors: yamashita k. Dig Dis. 2022;40(4):479-488. doi: 10.1159/000518099. Epub 2021 Jul 30. Dig Dis. 2022. PMID: 34348262 Free article.
Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality.
Higuchi M, Tamaki N, Kurosaki M, Inada K, Kirino S, Yamashita K, Hayakawa Y, Osawa L, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Itakura J, Loomba R, Enomoto N, Izumi N. Higuchi M, et al. Among authors: yamashita k. Aliment Pharmacol Ther. 2022 Feb;55(3):292-301. doi: 10.1111/apt.16745. Epub 2021 Dec 19. Aliment Pharmacol Ther. 2022. PMID: 34927277 Free PMC article.
Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy.
Sekiguchi S, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Okamoto R, Kurosaki M, Izumi N. Sekiguchi S, et al. Among authors: yamashita k. Cancer Rep (Hoboken). 2022 Nov;5(11):e1613. doi: 10.1002/cnr2.1613. Epub 2022 Mar 18. Cancer Rep (Hoboken). 2022. PMID: 35302279 Free PMC article.
Prediction of Therapeutic Response Using Contrast-Enhanced Ultrasound in Japanese Patients Treated with Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma.
Takada H, Yamashita K, Osawa L, Komiyama Y, Nakakuki N, Muraoka M, Suzuki Y, Sato M, Takano S, Fukasawa M, Yamaguchi T, Maekawa S, Enomoto N. Takada H, et al. Among authors: yamashita k. Oncology. 2023;101(3):173-184. doi: 10.1159/000527752. Epub 2022 Dec 14. Oncology. 2023. PMID: 36516803
5,472 results